Current and emerging strategies for management of myelodysplastic syndromes.

Abstract excerpt

Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis with varying degrees of dysplasia and peripheral cytopenias. MDS are driven by structural chromosomal alterations and somatic mutations in neoplastic myeloid cells, which are supported by a tumorigenic and a proinflammatory marrow microenvironment. Current treatment strategies for lower-risk MDS focus on improving quality of life and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biomarkers
• Share to Bone Marrow
• Share to Combined Modality Therapy